ASCO 2022 Conference Coverage


 

Lecture Summary - Pralsetinib in Patients (pts) With Advanced or Metastatic RET-Altered Thyroid Cancer (TC): Updated Data From the ARROW Trial

20 views
July 14, 2022
Comments 0
Login to view comments. Click here to Login